Localized Treatment with a Novel FDA-Approved Proteasome Inhibitor Blocks the Degradation of Dystrophin and Dystrophin-Associated Proteins in mdx Mice
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Duchenne Muscular Dystrophy (DMD) is an incurable inherited disease of childhood, characterized by progressive muscle degeneration and weakness. Our previous findings supported the idea that dystrophin and associated proteins, absent or greatly reduced in DMD, are degraded in dystrophin-deficient muscle by the proteasomal-dependent pathway. Indeed, treatment with the proteasome inhibitor MG-132 of skeletal muscles from mdx mice--a spontaneous mouse model of DMD--as well as from DMD patients, effectively rescued the expression and correct cellular localization of dystrophin and associated proteins. These promising results led us to further explore the use of proteasome inhibitors as a therapy for DMD. Therefore, we directed our attention towards two new dipeptide boronic acid inhibitors blocking the proteasomal-dependent degradation pathway: Velcade (bortezomib or PS-341) and MLN273 (PS-273). The exciting aspect of this development is that these drugs have already progressed to preclinical and clinical trials, in different fields than muscular dystrophy. Indeed, Velcade has been already FDA-approved for treatment of multiple myeloma and its side effects had been already explored and managed. Promisingly, MLN273 is currently in the preclinical trial phase. Here, we test the effectiveness of Velcade and MLN273 by local injection into the gastrocnemius muscle of mdx mice. We show the rescue of expression and membrane localization of alpha-dystroglycan, beta-dystroglycan, alpha-sarcoglycan, and dystrophin after Velcade and MLN273 localized treatment, versus untreated (PBS only) mdx mice. Intriguingly, we also show that localized treatment with Velcade and MLN273 reduces the activation of Nuclear Factor-kappaB (NFkB). Because the NFkB pathway has been shown to be involved in inflammation responses in myopathies and DMD, our current results may have important clinical implications. Clearly, more investigations are needed, but our results emphasize the effectiveness of the pharmacological approach as a potential treatment for Duchenne muscular dystrophy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dystrophin: the protein product of the Duchenne muscular dystrophy locus
Hoffman, E. P., Brown, R. H., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90579-4 · Cited by 4,693
Koenig, M., Hoffman, E. P., Bertelson, C. J., Monaco, A. P., Feener, C., & Kunkel, L. M. (1987) · Cell · doi:10.1016/0092-8674(87)90504-6 · Cited by 2,411
Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage
Campbell, K. P. (1995) · Cell · doi:10.1016/0092-8674(95)90344-5 · Cited by 829
Bonuccelli, G., Sotgia, F., Schubert, W., Park, D. S., Frank, P. G., Woodman, S. E., Insabato, L., Cammer, M., Minetti, C., & Lisanti, M. P. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63523-7 · Cited by 135
Self-citation
Cited by
Grounds, M. D., Radley, H. G., Lynch, G. S., Nagaraju, K., & De Luca, A. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.03.008 · Cited by 344
Misregulation of autophagy and protein degradation systems in myopathies and muscular dystrophies.
Sandri, M., Coletto, L., Grumati, P., & Bonaldo, P. (2013) · Journal of Cell Science · doi:10.1242/jcs.114041 · Cited by 179
“Indeed, use of proteasome inhibitors, such as MG132 and Velcade, has been found to result in the restoration of the normal protein levels and subcellular localization of bdystroglycan, a-sarcoglycan and dystrophin (Bonuccelli et al., 2007; Gazzerro et al., 2010).”
BackgroundProteasome inhibition improves the muscle of laminin α2 chain-deficient mice.
Carmignac, V., Quéré, R., & Durbeej, M. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddq499 · Cited by 58
Castets, P., Frank, S., Sinnreich, M., & Rüegg, M. A. (2016) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-160153 · Cited by 49
“Altered activity of the UPS contributes to muscle atrophy in neuromuscular disorders, such as MDC1A (congenital muscular dystrophy type 1) [4] and DMD (Duchenne muscular dystrophy) [5, 6].”
BackgroundThe proteasomal inhibitor MG132 prevents muscular dystrophy in zebrafish.
Winder, S. J., Lipscomb, L., Angela Parkin, C., & Juusola, M. (2011) · PLoS Currents · doi:10.1371/currents.rrn1286 · Cited by 30
“The Lisanti group further demonstrated that inhibition of the proteasome was able to restore other dystrophin glycoprotein complex (DGC) components in both mdx mice that lack dystrophin and in explants of DMD patients [ [15] , [16] ].”
Metadata
- Authors
- Bonuccelli, G., Sotgia, F., Capozza, F., Gazzerro, E., Minetti, C., & Lisanti, M. P.
- Venue
- Cell Cycle
- Publisher
- Informa UK Limited
- Published
- 2007-05-15
- Volume
- 6
- Issue
- 10
- Pages
- 1242-1248
- ISSN
- 1538-4101 (ISSN-L)
- 1551-4005
- OpenAlex
- W1964585686
- Cited by
- 75
- References
- 4
- FWCI
- 2.04
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Localized Treatment with a Novel FDA-Approved Proteasome Inhibitor Blocks the Degradation of Dystrophin and Dystrophin-Associated Proteins in mdx Mice. https://app.cochat.ai/papers/10.4161/cc.6.10.4182
- The paper
- Bonuccelli, G., Sotgia, F., Capozza, F., Gazzerro, E., Minetti, C., & Lisanti, M. P. (2007). Localized Treatment with a Novel FDA-Approved Proteasome Inhibitor Blocks the Degradation of Dystrophin and Dystrophin-Associated Proteins in mdx Mice. Cell Cycle. https://doi.org/10.4161/cc.6.10.4182
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.